Abstract: A long-term stabilized aqueous initiator composition initiates setting and hardening of aluminous cement compositions. The composition includes blocked calcium silicate cement and water. A method prepares the long-term stabilized aqueous initiator composition. A second method sets and hardens a curable aqueous-phase aluminous cement component. A mortar system includes the long-term stabilized aqueous initiator composition and a curable aqueous-phase aluminous cement component.

Abstract: A two-component mortar system chemically fastens anchors in mineral substrates. The system has a curable aqueous-phase aluminous cement component A and an initiator component B in an aqueous-phase for initiating a curing process. A ready-for-use two-component system for chemical fastening fastens anchors to metal elements, structures made of brickwork, concrete, pervious concrete or natural stone.

Abstract: A two-component mortar system chemically fastens anchors in mineral substrates. The two-component mortar system has a curable aqueous-phase aluminous cement component A and a component B in an aqueous-phase for initiating a curing process. The two-component mortar system is ready-to-use in a method for chemical fastening of anchors in mineral substrates.

Abstract: A multi-component inorganic capsule anchoring system can be used for chemical fastening of anchors, bolts, screw anchors, screw bolts, and post-installed reinforcing bars in mineral substrates. The multi-component inorganic capsule anchoring system contains a curable powdery ground-granulated blast-furnace slag-based component A, and an initiator component B in aqueous-phase for initiating the curing process. The powdery ground-granulated blast-furnace slag-based component A contains further silica dust. The component B contains an alkali- or alkaline earth-hydroxide, alkali- or alkaline earth-carbonate, or alkali- or alkaline earth-sulfate component.

Abstract: A multi-component inorganic capsule anchoring system can be used for chemical fastening of anchors, bolts, screw anchors, screw bolts, and post-installed reinforcing bars in mineral substrates. The multi-component inorganic capsule anchoring system contains a curable powdery ground-granulated blast-furnace slag-based component A, and an initiator component B in aqueous-phase for initiating the curing process. The powdery ground-granulated blast-furnace slag-based component A contains further silica dust. The component B contains an alkali- or alkaline earth-hydroxide, alkali- or alkaline earth-carbonate, or alkali-or alkaline earth-sulfate component.

Abstract: The present invention relates to novel compounds of general Formula II: wherein the groups X, and R1 to R4 have the meanings given in the description, to a process for preparing these compounds and to their use for treating, preventing or ameliorating viral infections and diseases which are associated with PLA2G16.

Abstract: A system for processing a pavement reinstatement, the system comprising: a weighing apparatus 502 for measuring a mass of reinstatement material; and a reinstatement apparatus 10 adapted to receive reinstatement dimension information and reinstatement material information and adapted to determine a required reinstatement material mass, whereby to provide a target air voids content of the reinstatement; optionally wherein the reinstatement apparatus is adapted to receive an indication of the mass measured by the weighing apparatus and optionally wherein the indication is a verification of the weighing apparatus having measured the required mass.

Abstract: A system for processing a pavement reinstatement includes a weighing apparatus (502) for measuring a mass of reinstatement material. A reinstatement apparatus (10) is adapted to receive reinstatement dimension information and reinstatement material information and adapted to determine a required reinstatement material mass, and to provide a target air voids content of the reinstatement. The reinstatement apparatus is optionally adapted to receive an indication of the mass measured by the weighing apparatus and the indication is a verification of the weighing apparatus having measured the required mass.

Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

Abstract: A system for processing a pavement reinstatement includes a weighing apparatus (502) for measuring a mass of reinstatement material. A reinstatement apparatus (10) is adapted to receive reinstatement dimension information and reinstatement material information and adapted to determine a required reinstatement material mass, and to provide a target air voids content of the reinstatement. The reinstatement apparatus is optionally adapted to receive an indication of the mass measured by the weighing apparatus and the indication is a verification of the weighing apparatus having measured the required mass.

Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: Described herein are compounds of Formula (I?), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.

Abstract: Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C—C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(?O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C?O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Abstract: Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(?O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C?O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6, X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterized by abnormal cell growth and/or dysregulated apoptosis.

Abstract: Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(?O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C?O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Abstract: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

Abstract: Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.